Friday, February 18, 2005

Pfizer / FDA Panel Vote on Cox 2

Just looking at the headline news on the FDA panel votes on Celebrex and Bextra can give investors a heart attack. I wasn't too concern with Celebrex, but I had my doubts on Bextra. Looks like the panel voted for both to remain on the market with additional warnings. Finally, some good news for Pfizer...


Post a Comment

<< Home